

Daiana Ibarretxe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5001374/publications.pdf>

Version: 2024-02-01

37
papers

816
citations

516561

16
h-index

526166

27
g-index

37
all docs

37
docs citations

37
times ranked

1341
citing authors

#	ARTICLE	IF	CITATIONS
1	Low HDL and high triglycerides predict COVID-19 severity. <i>Scientific Reports</i> , 2021, 11, 7217.	1.6	122
2	Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease. <i>Journal of Endocrinology</i> , 2017, 233, R173-R184.	1.2	86
3	HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3151.	1.8	58
4	Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels—The zero-LDL hypothesis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 292-299.e3.	0.6	51
5	The Circulating GRP78/BiP Is a Marker of Metabolic Diseases and Atherosclerosis: Bringing Endoplasmic Reticulum Stress into the Clinical Scenario. <i>Journal of Clinical Medicine</i> , 2019, 8, 1793.	1.0	40
6	Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2016, 28, 71-78.	0.4	35
7	Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia. <i>Advances in Therapy</i> , 2019, 36, 1786-1811.	1.3	35
8	Long-term exposure to PM10 above WHO guidelines exacerbates COVID-19 severity and mortality. <i>Environment International</i> , 2022, 158, 106930.	4.8	32
9	Toward a new clinical classification of patients with familial hypercholesterolemia: One perspective from Spain. <i>Atherosclerosis</i> , 2019, 287, 89-92.	0.4	29
10	Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. <i>Cardiovascular Diabetology</i> , 2016, 15, 107.	2.7	28
11	Novel mutations in the GPIHBP1 gene identified in 2 patients with recurrent acute pancreatitis. <i>Journal of Clinical Lipidology</i> , 2016, 10, 92-100.e1.	0.6	27
12	Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets. <i>Current Cardiology Reports</i> , 2020, 22, 66.	1.3	26
13	How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?. <i>Atherosclerosis</i> , 2017, 262, 107-112.	0.4	22
14	Molecular basis of the familial chylomicronemia syndrome in patients from the National Dyslipidemia Registry of the Spanish Atherosclerosis Society. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1482-1492.e3.	0.6	22
15	Increasing long-chain n-3PUFA consumption improves small peripheral artery function in patients at intermediate—high cardiovascular risk. <i>Journal of Nutritional Biochemistry</i> , 2014, 25, 642-646.	1.9	19
16	Detecting familial hypercholesterolemia earlier in life by actively searching for affected children: The DECOPIN project. <i>Atherosclerosis</i> , 2018, 278, 210-216.	0.4	18
17	Evaluation of the chylomicronTG to VLDLâ€”TG ratio for type I hyperlipoproteinemia diagnostic. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13345.	1.7	16
18	Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. <i>Journal of Clinical Lipidology</i> , 2018, 12, 211-218.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1452-1462.	0.6	14
20	Dietary intake and lipid levels in Norwegian and Spanish children with familial hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1299-1307.	1.1	14
21	Patients With Systemic Lupus Erythematosus Show an Increased Arterial Stiffness That is Predicted by IgM Anti- β_2 -Glycoprotein I and Small Dense High-Density Lipoprotein Particles. <i>Arthritis Care and Research</i> , 2019, 71, 116-125.	1.5	12
22	Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 197.	1.4	12
23	Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia. <i>Atherosclerosis</i> , 2018, 270, 117-122.	0.4	11
24	Impact of epidermal fatty acid binding protein on 2D-NMR-assessed atherogenic dyslipidemia and related disorders. <i>Journal of Clinical Lipidology</i> , 2016, 10, 330-338.e2.	0.6	9
25	Valor de los parámetros lipídicos y apoproteicos para la detección de hipercolesterolemia familiar en la infancia. Proyecto DECOPIN. <i>Clínica E Investigación En Arteriosclerosis</i> , 2018, 30, 170-178.	0.4	9
26	Documento de consenso de un grupo de expertos de la Sociedad Española de Arteriosclerosis (SEA) sobre el uso clínico de la resonancia magnética nuclear en el estudio del metabolismo lipoproteico (Liposcale). <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 219-229.	0.4	9
27	Serum glycoproteins A and B assessed by 1H-NMR in familial hypercholesterolemia. <i>Atherosclerosis</i> , 2021, 330, 1-7.	0.4	9
28	Hipercolesterolemia familiar en la infancia y la adolescencia: una realidad oculta. <i>Clínica E Investigación En Arteriosclerosis</i> , 2017, 29, 129-140.	0.4	8
29	Caveolin 3 deficiency myopathy associated with dyslipidemia: Treatment challenges and possible pathophysiological association. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1280-1283.	0.6	6
30	Low-carbohydrate, high-protein, high-fat diet alters small peripheral artery reactivity in metabolic syndrome patients. <i>Clínica E Investigación En Arteriosclerosis</i> , 2014, 26, 58-65.	0.4	5
31	Relationship Between Fatty Acid Binding Protein 4 and Liver Fat in Individuals at Increased Cardiometabolic Risk. <i>Frontiers in Physiology</i> , 2021, 12, 781789.	1.3	5
32	Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 775677.	1.5	4
33	Metabolismo de los triglicéridos y clasificación de las hipertrigliceridemias. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 1-6.	0.4	3
34	Efficacy of therapeutic lifestyle changes on lipid profiles assessed by NMR in children with familial and non-familial hypercholesterolemia. <i>Clínica E Investigación En Arteriosclerosis</i> , 2020, 32, 49-58.	0.4	3
35	Patrón de metilación en ADN de sujetos hipertrigliceridémicos. <i>Clínica E Investigación En Arteriosclerosis</i> , 2022, 34, 27-32.	0.4	2
36	El rastreo masivo de datos es una segunda oportunidad para mejorar el manejo de los pacientes fenotipo de hipercolesterolemia familiar. <i>Clínica E Investigación En Arteriosclerosis</i> , 2021, 33, 138-147.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Magnetic resonance-assessed lipoprotein profile. The time has come for its clinical use. Revista Espanola De Cardiologia (English Ed), 2021, 75, 5-5.	0.4	0